Svitlana V. V Antonenko

Dr. Svitlana V. V Antonenko


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ASAladdin Y. Shchaslyvyi
Aladdin Y. Shchaslyvyi
SASvitlana V. V Antonenko
Svitlana V. V Antonenko
MTMaksym G. Tesliuk
Maksym G. Tesliuk
GTGennadiy D. Telegeev
Gennadiy D. Telegeev
In the realm of gene therapy, a pivotal moment arrived with Paul Berg’s groundbreaking identification of the first recombinant DNA in 1972. This achievement set the stage for future breakthroughs. Conditions once considered undefeatable, like melanoma, pancreatic cancer, and a host of other ailments, are now being addressed at their root cause—the genetic level. Presently, the gene therapy landscape stands adorned with 22 approved in vivo and ex vivo products, including IMLYGIC, LUXTURNA, Zolgensma, Spinraza, Patisiran, and many more. In this comprehensive exploration, we delve into a rich assortment of 16 drugs, from siRNA, miRNA, and CRISPR/Cas9 to DNA aptamers and TRAIL/APO2L, as well as 46 carriers, from AAV, AdV, LNPs, and exosomes to naked mRNA, sonoporation, and magnetofection. The article also discusses the advantages and disadvantages of each product and vector type, as well as the current challenges faced in the practical use of gene therapy and its future potential.

ASAladdin Y. Shchaslyvyi
Aladdin Y. Shchaslyvyi
SASvitlana V. V Antonenko
Svitlana V. V Antonenko
GTGennadiy D. Telegeev
Gennadiy D. Telegeev
The connection between chronic psychological stress and the onset of various diseases, including diabetes, HIV, cancer, and cardiovascular conditions, is well documented. This review synthesizes current research on the neurological, immune, hormonal, and genetic pathways through which stress influences disease progression, affecting multiple body systems: nervous, immune, cardiovascular, respiratory, reproductive, musculoskeletal, and integumentary. Central to this review is an evaluation of 16 Behavioral Stress Reduction Programs (BSRPs) across over 200 studies, assessing their effectiveness in mitigating stress-related health outcomes. While our findings suggest that BSRPs have the potential to enhance the effectiveness of medical therapies and reverse disease progression, the variability in study designs, sample sizes, and methodologies raises questions about the generalizability and robustness of these results. Future research should focus on long-term, large-scale studies with rigorous methodologies to validate the effectiveness of BSRPs.

16 August 2024 in Polymers
Verified
Journal Article
Open access
PDF file
GZGanna Zubova
Ganna Zubova
HMHanna Melnyk
Hanna Melnyk
IZI. Zaets
I. Zaets
TSTetyana Sergeyeva
Tetyana Sergeyeva
Olesia HavryliukOlesia Havryliuk
Olesia Havryliuk
NKNatalia Kozyrovska
Natalia Kozyrovska
Polymer-based dressings deriving from natural biomaterials have advantages such as nontoxicity, biocompatibility, and mechanical stability, which are essential for efficient wound healing and microbial infection diagnostics. Here, we designed a prototype of an intelligent hydrogel dressing on the base of bacterial cellulose (BC) for monitoring wound microbial infection due to the uploaded natural pH dye-sensor, anthocyanins (ANC) of elderberry fruit (Sambucus nigra L.). The highest sensor responses to bacterial metabolites for ANC immobilized to BC were observed at pH 5.0 and 6.0. The detection limit of the sensor signals was 3.45 A.U., as it was evaluated with a smartphone-installed application. The FTIR spectral analysis of the hybrid BC/ANC hydrogel films has proved the presence of anthocyanins within the BC matrix. Hybrid films differed from the control ones by thicker microfibrils and larger pores, as detected with scanning electron microscopy. Halochromic BC/ANC films exhibited antimicrobial activities mainly against gram-positive bacteria and yeast. They showed no cytotoxicity for the in vitro human cell lines and mouse fibroblasts within a selected range of anthocyanin concentrations released from the BC/ANC film/dressing prototype. Compared to the control, the in vitro healing test showed overgrowth of primary mouse fibroblasts after applying 0.024–2.4 µg/mL ANC.

1 June 2023 in Experimental Oncology
Verified
Journal Article
Open access
SASvitlana V. V Antonenko
Svitlana V. V Antonenko
GTG.D. Telegeev
G.D. Telegeev
Summary. Aim: To analyze interaction of ubiquitin specific peptidase 1 (USP1) with Bcr-Abl and to assess the relation between USP1 functional activity and Bcr-Abl expression in K562 chronic myeloid leukemia cells. Materials and Methods: The interaction between USP1 and Bcr-Abl in K562 cells was analyzed by co-immunoprecipitation, Western blot analysis, and confocal microscopy. Results: A direct interaction between Bcr-Abl oncoprotein and USP1 protein in K562 cells was established by co-immunoprecipitation. Immunofluorescence analysis and confocal microscopy revealed that Bcr-Abl/USP1 protein complex is formed in the cell nucleus. The inhibition of USP1 protein activity by ML323 reduced the level of Bcr-Abl oncoprotein in K562 cells. Conclusions: USP1 protein has been identified as a new protein partner of Bcr-Abl oncoprotein in chronic myeloid leukemia. The relationship between the functional activity of USP1 protein and the level of Bcr-Abl oncoprotein has been demonstrated, suggesting that the targeted inhibition of USP1 activity could be a challenging approach for reducing Bcr-Abl expression.

1 January 2020 in Cytology and Genetics
Verified
Journal Article
Closed access
PDF file
SASvitlana V. V Antonenko
Svitlana V. V Antonenko
IKIhor Kravchuk
Ihor Kravchuk
GTG. D. Telegeev
G. D. Telegeev
Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disease characterized by the occurrence of the Bcr-Abl fusion oncoprotein, which resulted fro

27 July 2023 in Cytology and Genetics
Verified
Journal Article
Closed access
PDF file
SASvitlana V. V Antonenko
Svitlana V. V Antonenko
DGD. S. Gurianov
D. S. Gurianov
IKI. V. Kravchuk
I. V. Kravchuk
MDMykhaylo Dybkov
Mykhaylo Dybkov
LSL. P. Shvachko
L. P. Shvachko
GTG. D. Telegeev
G. D. Telegeev
Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm resulting from the emergence of abnormal hematopoietic stem cells carrying a Bcr-Abl on